Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials"

Diabetes Obes Metab. 2018 Sep;20(9):2319-2320. doi: 10.1111/dom.13366. Epub 2018 Jun 10.

Authors

Richard D Leslie¹, Paolo Pozzilli^{1

2}, Anne L Peters³, Raffaella Buzzetti⁴, Sudha S Shankar⁵, Zvonko Milicevic⁶, Imre Pavo⁶, Jeremie Lebrec⁷, Sherry Martin⁵, Nanette C Schloot⁷

Affiliations

¹ Blizard Institute, London, UK.
² Department of Endocrinology & Diabetes, University Campus Bio-Medico, Rome, Italy.
³ Keck School of Medicine of USC, Los Angeles, California.
⁴ Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.
⁵ Eli Lilly and Company, Indianapolis, Indiana.
⁶ Eli Lilly and Company, Vienna, Austria.
⁷ Lilly Deutschland GmbH, Bad Homburg, Germany.

PMID: 29781106
DOI: 10.1111/dom.13366

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Autoantibodies
Diabetes Mellitus, Type 1
Glucagon-Like Peptides* / analogs & derivatives
Humans
Immunoglobulin Fc Fragments
Latent Autoimmune Diabetes in Adults*
Recombinant Fusion Proteins

Substances

Autoantibodies
Immunoglobulin Fc Fragments
Recombinant Fusion Proteins
Glucagon-Like Peptides
dulaglutide